For example, the BCL2 inhibitor venetoclax is approved for the treatment of several haematological malignancies, and the dual CIAP1/XIAP inhibitor tolinapant was granted orphan drug designation from the United States Food and Drugs Administration (FDA) for the treatment of T-cell lymphoma in 2020. This evidence concerns the gene BIRC2 and T-cell non-Hodgkin lymphoma.